EP3687540A1 - Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon - Google Patents

Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon

Info

Publication number
EP3687540A1
EP3687540A1 EP18859565.6A EP18859565A EP3687540A1 EP 3687540 A1 EP3687540 A1 EP 3687540A1 EP 18859565 A EP18859565 A EP 18859565A EP 3687540 A1 EP3687540 A1 EP 3687540A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
cycloalkyl
independently selected
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859565.6A
Other languages
English (en)
French (fr)
Other versions
EP3687540A4 (de
Inventor
Xiaohu Zhang
Jiyue ZHENG
Haikuo MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cgenetech Suzhou China Co Ltd
Original Assignee
Cgenetech Suzhou China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810265417.9A external-priority patent/CN110317191B/zh
Priority claimed from CN201810710340.1A external-priority patent/CN110669036B/zh
Priority claimed from CN201811034891.7A external-priority patent/CN109553604B/zh
Application filed by Cgenetech Suzhou China Co Ltd filed Critical Cgenetech Suzhou China Co Ltd
Publication of EP3687540A1 publication Critical patent/EP3687540A1/de
Publication of EP3687540A4 publication Critical patent/EP3687540A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage

Definitions

  • the present invention generally relates to heteroaryl compounds and, more particularly, relates to novel heteroaryl compounds that are useful in the therapies targeting C-X-C chemokine receptor type 4 (CXCR4) inhibitors, and use of the CXCR4 inhibitors for therapeutic intervention in infectious diseases, inflammatory diseases, tumors, and cancers.
  • CXCR4 C-X-C chemokine receptor type 4
  • C-X-C chemokine receptor type 4 (CXCR4) is a transmembrane protein that belongs to the G-protein-coupled receptors and it is involved in physiological processes in the hematopoietic and immune systems. Studies show that CXCR4 is expressed in tissues including lymphatic tissues, thymus, brain, spleen, stomach and small intestine. CXCR4 /transmits signals from its natural chemokine ligand, stromal cell-derived factor (SDF)-la, to intracellular biological pathways via G-proteins.
  • SDF stromal cell-derived factor
  • CXCR4 and SDF-la have been targeted in various therapeutic treatments for a number of diseases, including, for example, human immunodeficiency virus (HIV) infection, cancers, tumors, and inflammation and autoimmune disease such as rheumatoid arthritis and allergic asthma.
  • HIV human immunodeficiency virus
  • Plerixafor was approved by the FDA in 2008 for the mobilization of hematopoietic stem cells. See Cho W.T.. et al., /. Med. Chem. 2011; 55: 977-94; Debnath B. et al., Theranostics 2013, 3 (1): 47-75.
  • heteroaryl compounds as CXCR4 inhibitors, and compositions and applications thereof. These disclosed heteroaryl compounds, and compositions and applications thereof, may effectively inhibit necrosis, thereby finding application in treatments of necrotic pathway-related diseases and disorders, including, for example, inflammation, tumors, metabolic diseases and neurodegenerative diseases such as cerebral ischemia and stroke.
  • Ar is 5-10 membered heteroaryl comprising one N and 1-3 additional heteroatoms independently selected from the group consisting of N, O, and S, and Ar is unsubstituted or substituted with 1-4 I1 ⁇ 2;
  • W is , each X is independently a bond, CR 3 2R 33 , O, NR 3 4,
  • Y is , wherein the carbon bonded with R 3 is bonded with the carbon bonded with R2;
  • D 3 is N or CR' 4
  • Di is NR' 4 , O, S or C(R' 4 ) 2 ,
  • D 3 is N or CR' 4
  • O t is NR' 4
  • D 2 is
  • R 7 is selected from the group consisting of H, deuterium, Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6
  • each of Rg and R9 is independently selected from the group consisting of H, deuterium, -CN, Ci-6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C 1 -3 alkoxy; or R 7 and Rg, and atoms attached thereto, form a ring;
  • R 3 1 is selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci -8 alkoxy, C2-6 alkynyl, C2-6 alkenyl, -S(Ci_6 alkyl), -NH(Ci_6 alkyl), -N(Ci_6 alkyl) 2 , aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_
  • the disclosed compound is according Formula la
  • Ar is unsubstituted or substituted with 1-4 groups of R 3 1, and Ar is selected from the group consisting of:
  • each X is independently a bond, CR 3 2R 33 , O, or NR 3 4;
  • each of R19, R20, R21, R22, R25, R26, R27, R28, R29, and R30 is independently selected from the group consisting of H, deuterium, -CN, -OH, Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R19 and R27, together with atoms they attached to, form a ring; or R21 and R27, together with atoms they attached to, form a ring;
  • each of R2 3 and R24 is independently selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R22 and R2 3 , together with atoms they attached to, form a 5-7 membered heterocycle;
  • R 3 1 is selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, -S(Ci_6 alkyl), -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 al
  • the disclosed compound is according to Formula lb:
  • Ar is unsubstituted or substituted with 1-4 groups of R31 , and Ar is selected from the group consisting of:
  • each X is independently a bond, CR 3 2R 33 , O, or NR 3 4;
  • each of R19, R20, R21, R22, R25, R26, R27, R28, R29, and R30 is independently selected from the group consisting of H, deuterium, -CN, -OH, Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R19 and R27, together with atoms they attached to, form a ring; or R21 and R27, together with atoms they attached to, form a ring;
  • each of R2 3 and R24 is independently selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R22 and R2 3 , together with atoms they attached to, form a 5-7 membered heterocycle;
  • R 3 1 is selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, -S(Ci_6 alkyl), -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 al
  • the disclosed compound is according to Formula Ic:
  • each of Zl, Z2 and Z3 is independently selected from the group consisting of O and
  • each of R41 and R42 is independently selected from the group consisting of H, deuterium, halide and C1-3 alkyl.
  • each of R19, R20, R21, R22, R25, R26, R27, R28, R29, and R30 is independently selected from the group consisting of H, deuterium, -CN, -OH, Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, Ci_6 alkyl, and C1-3 alkoxy;
  • each of R2 3 and R24 is independently selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R22 and R2 3 , together with atoms they attached to, form a 5-7 membered heterocycle; and each of R and R' is independently selected from the group consisting of H, Ci_6 alkyl, C 3- 6 cycloalkyl, and C 3 -8 heterocycloalkyl comprising N or O, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -8 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium,
  • the disclosed compound is selected from the group consisting of:
  • the disclosed compound is according to Formula II:
  • R2 3 is selected from the group consisting of H, Ci_6 alkyl and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(C 1-6 alkyl) 2 , and Ci_ 3 alkoxy;
  • Ci_ 6 alkyl, C 3 - 6 cycloalkyl, and C 3 -6 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C 3 -6 cycloalkyl, C1-3 alkoxy, and C 3 -6 heterocycloalkyl comprising N or O; or R and R24, together with N atom they attached to, form a 5-7 membered heterocycle; and
  • the disclosed compound is according to
  • Ar is unsubstituted or substituted with 1-4 groups of R31 , and Ar is selected from the group consisting of:
  • the disclosed compound is according to
  • each of Di, D2 and D3 is independently selected from the group consisting of N and CR' 4 ;
  • Ar is unsubstituted or substituted with 1-4 groups of R 3 1, and Ar is selected from the group consisting of:
  • R2 3 is selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(C 1-6 alkyl) 2 , and Ci_ 3 alkoxy;
  • Ci_ 6 alkyl and C 3 - 6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C 3 -6 cycloalkyl, C1-3 alkoxy, and C 3 -6 heterocycloalkyl comprising N or O; or R and R24, together with atoms they attached to, form a 5-7 membered heterocycle;
  • R' is selected from the group consisting of H, Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -8 heterocycloalkyl comprising N or O, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -8 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci-3 alkoxy; or R' and R21, together with atoms they attached to, form a 5-7 membered heterocycle.
  • the disclosed compound is according to Formula III:
  • each of Ai, A 2 , and A 3 is independently selected from the group consisting of N and CR44, wherein at least one of Ai, A 2 , and A 3 is N;
  • each of R5 and R 6 is independently selected from the group consisting of H, deuterium, -CN, Ci-6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(Ci_6 alkyf ,
  • R 5 is O or CR ⁇ Rte, and R ⁇ and R5, together with atoms they attached to, form a ring;
  • R 7 is selected from the group consisting of H, Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl comprising an O, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl comprising an O;
  • each of Rg and R9 is independently selected from the group consisting of H, deuterium, -CN, Ci-6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C1-3 alkoxy; or R 7 and Rg, and atoms attached thereto, form a ring;
  • R44 is H, deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci -8 alkoxy,
  • R2 3 is selected from the group consisting of H, Ci_6 alkyl and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(C 1-6 alkyl) 2 , and Ci_ 3 alkoxy;
  • each of R and R24 is independently selected from the group consisting of H, Ci_6 alkyl,
  • Ci_ 6 alkyl, C 3 - 6 cycloalkyl, and C 3 -6 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C 3 -6 cycloalkyl, C1-3 alkoxy, and C 3 -6 heterocycloalkyl comprising N or O; or R and R24, together with N atom they attached to, form a 5-7 membered heterocycle; or R and R21, together with N atom they attached to, form a 5-7 membered heterocycle;
  • each of R45 and R 3 ⁇ 4 is independently selected from the group consisting of H, deuterium, halide, C1-3 alkyl; or R45 and R4 6 , together with the atoms they attached to, form a ring.
  • the disclosed compound is according to
  • each of Ei, E 2 , and E3 is independently selected from the group consisting of O and
  • each of R45 and R 3 ⁇ 4 is independently selected from the group consisting of H, deuterium, halide, C1-3 alkyl; or R45 and R4 6 , together with the atoms they attached to, form a ring.
  • the disclosed compound is according to formula Ilia and Illb, and each of Ei, E 2 , and E 3 is independently selected from the group
  • the disclosed compound is according to formula Ilia and Illb, and each of Ai and A2 is independently selected from the group consisting of N and CR44, wherein at least one of Ai and A2 is N;
  • -C(R5R 6 )W2 is selected from the group consisting of:
  • U is unsubstituted or substituted with is unsubstituted or substituted with 1-3 groups selected from the group consisting of deuterium, halide, -OH, C1-3 alk l, and C1-3 alkox , and U is selected from the rou consistin of:
  • Another aspect of the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formulas I, la, lb, Ic, II, Ila, lib, III, Ilia, and Illb or other compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, and a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.
  • Another aspect of the present disclosure provides a combination composition comprising:
  • Another aspect of the present disclosure provides a compound of formulas I, la, lb, Ic, II,
  • FIG. 1 depicts the 12G5 assay by compound A42.
  • FIG. 2 depicts the 12G5 assay by compound A43.
  • FIG. 3 depicts the 12G5 assay by compound A78.
  • FIG. 4 depicts the 12G5 assay by compound A83.
  • alkyl generally refers to a straight or branched chain saturated aliphatic hydrocarbon.
  • Alkyl groups include groups having from 1 to 8 carbon atoms (Ci-C 8 alkyl), from 1 to 6 carbon atoms (Ci-C 6 alkyl) and from 1 to 4 carbon atoms (Ci-C 4 alkyl), including, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, icri-butyl, pentyl, 2- pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl.
  • a substituent of an alkyl group is specifically indicated.
  • cyanoalkyl refers to an alkyl group substituted with at least one cyano substituent.
  • alkenyl as used herein generally refers to straight or branched chain alkene groups, which comprise at least one unsaturated carbon-carbon double bond.
  • Alkenyl groups include C2-C 8 alkenyl, C2-C 6 alkenyl and C2-C4 alkenyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively, including, for example, ethenyl, allyl or isopropenyl.
  • alkynyl as used herein generally refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond.
  • Alkynyl groups include C2-C 8 alkynyl, C2-C 6 alkynyl and C2-C4 alkynyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively.
  • cycloalkyl as used herein generally refers to a group that comprises one or more saturated rings in which all ring members are carbon, including, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl. Cycloalkyl groups do not comprise an aromatic ring or a heterocyclic ring. For example, certain cycloalkyl groups are
  • cycloalkyl in which the cycloalkyl group contains a single ring having from 3 to 7 ring members, all of which are carbon.
  • cycloalkenyl as used herein generally refers to a group that comprises one or more unsaturated rings in which all ring members are carbon.
  • alkoxy generally refers to an alkyl group as described above attached via an oxygen bridge.
  • Alkoxy groups include Ci-C 6 alkoxy and C1-C4 alkoxy groups, which have from 1 to 6 or from 1 to 4 carbon atoms, respectively.
  • Methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, seobutoxy, i ⁇ ?ri-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy are representative alkoxy groups.
  • alkylamino generally refers to a secondary or tertiary amine that has the general structure -NH-R1 or -N(R1)(R2), wherein Rl and R2 are selected independently from alkyl, cycloalkyl and (cycloalkyl)alkyl groups.
  • groups include, but are not limited to, for example, mono- and di-(Ci-C6 alkyl)amino groups, in which each Ci-C 6 alkyl may be the same or different.
  • alkyl as used in the term “alkylamino” differs from the definition of "alkyl” used for all other alkyl-containing groups, in the inclusion of cycloalkyl and (cycloalkyl)alkyl groups.
  • alkylthio as used herein generally refers to an alkyl-substituted thio group, wherein the term alkyl is as defined above.
  • halogen or "halide” as used herein generally refers to fluorine, chlorine, bromine, and iodine.
  • haloalkyl as used herein generally refers to an alkyl group that is substituted with one or more independently chosen halogens (e.g., "Ci-C 6 haloalkyl” groups have from 1 to 6 carbon atoms and at least one halogen).
  • haloalkyl groups include, but are not limited to, mono-, di- or tri-fluoromethyl; mono-, di- or tri-chloromethyl; mono-, di-, tri-, tetra- or penta-fluoroethyl; mono-, di-, tri-, tetra- or penta-chloroethyl; and 1,2,2,2- tetrafluoro-l-trifluoromethyl-ethyl.
  • heteroaryl as used herein generally refers to an aromatic group in which at least one aromatic ring comprises at least one heteroatom selected from N, O and S.
  • Heteroaryls include, for example, 5-12 membered heteroaryls. Examples include, but are not limited to, imidazole, furan, furazan, isothiazole, isoxazole, oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, tetrazole, thiazole and thiophene.
  • heterocycloalkyl as used herein generally refers to a ring structure containing
  • 3-12 ring atoms in which in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S.
  • examples include, but are not limited to, aziridine, oxiran, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, and
  • heterocyclic or “heterocycle” as used herein generally refers to a ring structure containing 3-12 ring atoms, in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S.
  • a heterocyclic group may be aromatic or non-aromatic.
  • Piperidine and oxetane are non-limiting examples of non-aromatic heterocycles.
  • Thiazole and pyridine are non-limiting examples of aromatic heterocycles.
  • substituted and “substituted,” as used herein, generally denote that a molecular moiety is covalently bonded to an atom within a molecule of interest.
  • a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member.
  • Substituents of aromatic groups are generally covalently bonded to a ring carbon atom.
  • a straight chain substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a member of a straight chain.
  • pharmaceutically acceptable generally refers to a form of the compound that is safe for administration to a subject.
  • a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of formula I which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
  • FDA Food and Drug Administration
  • salts generally refers to salts, commonly used to form alkali metal salts and to form addition salts of free acids or free bases, which have been approved by a regulatory agency. Salts are formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
  • the compound(s) of formulas I, la, lb, Ic, II, Ila, lib, III, Ilia, and Illb is used to treat a subject by administering the compound(s) as a pharmaceutical composition.
  • the compound(s) in one embodiment, is combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.
  • excipient generally refers to any pharmaceutically acceptable additive, carrier, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes.
  • diluent generally refers to an agent used as filler in order to achieve the desired composition volume or weight.
  • the diluent may be present in the pharmaceutical composition within granules in the form of a single compound or in the form of a mixture of compounds.
  • Non-limiting examples of diluent include lactose, starch,
  • pregelatinized starch microcrystalline cellulose, silicified microcrystalline cellulose, cellulose acetate, dextrose, mannitol, sodium phosphate, potassium phosphate, calcium phosphate, fructose, maltose, sorbitol, or sucrose.
  • adjuvant generally refers to any substance or mixture of substances that increases the efficacy or potency of a compound disclosed herein on a target where the adjuvant is used together with the compound disclosed herein. However, when the adjuvant is used alone, no pharmacological effect is observed on the same target.
  • the terms “treat”, “treating,” “treatment,” and “therapy” as used herein generally refer to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy.
  • Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.
  • the phrase "effective amount” as used herein generally refers to quantifying the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.
  • the effective amount in one embodiment, is administered in a single dosage form or in multiple dosage forms.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms or by other conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an effective amount of the active ingredient to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular hedgehog inhibitor employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. The mode of administration can have a large effect on dosage. Higher doses may be used for localized routes of delivery.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Dosages for a given compound disclosed herein are readily determinable by those of skill in the art by a variety of means.
  • One embodiment provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I, or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • the compounds described herein are formulated into
  • compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • a summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed., Easton, Pa.: Mack Publishing Company (1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania (1975); Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y.
  • a pharmaceutical composition refers to a mixture of a compound of formula I with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof.
  • pharmaceutically acceptable inactive ingredients such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or
  • the pharmaceutical composition facilitates administration of the compound to an organism.
  • therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated.
  • the mammal is a human.
  • a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
  • the compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
  • the pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.
  • the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
  • dosage units are tablets or capsules. In some embodiments, these contain an amount of active ingredient from about 1 to 2000 mg, advantageously from about 1 to 500 mg, and typically from about 5 to 150 mg.
  • a suitable daily dose for a human or other mammal vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods and practices.
  • Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion.
  • Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
  • Methods of the present invention may include the use of at least one compound of
  • Formulas I, la, lb, Ic, II, Ila, lib, III, Ilia, and Illb which inhibits necrosis in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, and have therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc.
  • the methods and compositions of the present invention include the use of the subject inhibitors for all such uses as inhibitors of necrosis may be implicated.
  • the subject methods can be performed on cells which are provided in culture (in vitro), or on cells in a whole animal (in vivo).
  • the compounds of the present invention can be prepared using various synthetic routes, including those described below, starting from commercially available materials.
  • Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.
  • the invention further encompasses "intermediate" compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all "intermediates" included in the invention. Further, structures produced by using starting materials in the form of a reactive derivative or salt, or produced by a compound obtainable by means of the process according to the invention and structures resulting from processing the compounds of the invention in situ are also within the scope of the invention.
  • New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In select embodiments, such starting materials are used and reaction conditions so selected as to obtain the desired compound(s).
  • Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Protecting groups, their introduction and removal are described above.
  • a work-up involves generally quenching of a reaction to terminate any remaining catalytic activity and starting reagents. This is generally followed by addition of an organic solvent and separation of the aqueous layer from the organic layer. The product is typically obtained from the organic layer and unused reactants and other spurious side products and unwanted chemicals are generally trapped in the aqueous layer and discarded.
  • the work-up in standard organic synthetic procedures found throughout the literature is generally followed by drying the product by exposure to a drying agent, such as anhydrous Na 2 S0 4 , to remove any excess water or aqueous byproducts remaining partially dissolved in the organic layer and concentration of the remaining organic layer.
  • Concentration of product dissolved in solvent may be achieved by any known means, such as evaporation under pressure, evaporation under increased temperature and pressure, and the like. Such concentrating may be achieved by use of standard laboratory equipment such as rotary-evaporator distillation, and the like. This is optionally followed by one or more purification steps which may include, but is not limited to, flash column
  • the compounds of the present invention can be prepared using various synthetic routes, including those described by methods A-N, BA-BS and AA-AT below, starting from
  • Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processed described in the methods and examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.
  • chloropyrimidine may be achieved with POCl 3 (step b).
  • Step a Substituted 4-chloro-3-oxobutanoate could also be reacted with amidine and DBU to give the pyrimidine intermediate (step a). Conversion of the hydroxypyrimidine to the chloropyrimidine may be achieved with POCl 3 (step b).4-aminopyrimidine core may be synthesized via methyl amine substitution (step c) followed by condensation of
  • Pyrimidine-4-carbaldehyde core could be synthesized via cyclization to the pyrimidine core (step a) followed by condensation of hydroxypyrimidine with corresponded amine (step b), following hydrolysis (step c).
  • the key intermediate 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylthio)pyrimidine may be formed via cyclization followed condensation 6- (dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol with 1-methylpiperazine (step b) .
  • 2- subsituted Pyrimidine-4-carbaldehyde core could be synthesized via oxidation of methyl sulfide to methylsulfonyl (step c), substitution with corresponding alcohol (step f) or amine (step d) followed by hydrolysis (step e, g) or can be formed by Suzuki coupling (step h) followed hydrolysis (step i).
  • the targeted compounds may be formed via cyclization (step a) followed condensation hydroxypyrimidine with 1-methylpiperazine (step b), following substitution with corresponding amine (step c).
  • 4-(4-methylpiperazin- l-yl)pyrimidine core can be achieved by condensation the amino acid with 2,2-dimethyl-l ,3-dioxane-4,6-dione followed decarboxylation (step a); following cyclization (step b) followed condensation hydroxypyrimidine with 1-methylpiperazine (step c) and at last de-Boc protective group (step c).
  • step a W n 0 ⁇ ⁇
  • heteroaromatic core could be substituted with bromine treated with NBS and free radical initiator.
  • the 2-methyl-5-nynaopyrimidine core may be achieved by cyclization (step a) followed condensation hydroxypyrimidine with corresponding amine (step b), following chlorination (step c) and substitution with corresponding amine (step d).
  • 5-bromo-2-(bromomethyl)imidazo[l,2-a]pyridine may be synthesized by 6- bromopyridin-2-amine cyclization with ethyl 3-bromo-2-oxopropanoate (step a), and then followed by reduction with NaBH 4 (step b) and bromination with PBr 3 (step c).
  • the targeted core can be synthesized via the reductive amination(step a, b) with the ketone, or followed the reductive amination(step c) again with the aldehyde, then de- protective group treated with TFA (step d).
  • the targeted core may be achieved by chlorination (step a) with TCCA and substitution with corresponding amine (step b).
  • the intermediate l-(3-aminopyridin-2-yl)ethan-l-one may be formed by substitution with (4-methoxyphenyl)methanamine (step a) followed Grignard reaction using CHsMgCl (step b), then de-PMB group with TFA (step c).
  • the targeted compounds can be obtained by acylation (step c) or mesylation (step d).
  • step e The 2-(pyrrolidin-2-yl)pyridine(S/R) can be formed by Grignard reaction with picolinonitrile and hydrolysis (step a), following the reductive animation with (4- methoxyphenyl)ethan-l-amine (R/S) (step b, d), then de-protective group treated with TFA (step c, e).
  • racemic 2-(3-methylpyrrolidin-2-yl)pyridine may achieved by imidization catalysis by TsOH (step a) followed Michael addition reaction treatment with ethyl (E)-but-2- enoate (step b), following formation lactam with con. HCl (step c), then reduction using L1AIH 4 (step d).
  • the Picolinaldehyde may be reacted with aminoacetonitrile to generate the Schiff base.
  • Pyrrole ring could be made via a [3 + 2] cyclization.
  • the cyano group could be knock out by a series of reductive reaction.
  • the substituted 8-nitroquinoline can be formed by cyclization treatment gly with 2-nitroaniline (step a), then substituted 8-nitroquinoline was reduced to the 8- aminoquinoline core with Pd/C(step b).
  • the 8-aminoquinolinecore could be methylated using methyl iodide.
  • the quinoline containing core can be formed by cyclization treatment gly with 2-fluoroaniline (step a)and substitution with corresponding amine (step b).
  • the PMB protective group could be removed under the acid condition.
  • 8-chloro-l,7-naphthyridine can be formed via cyclization (step a), then chlorination through Sandmeyer reaction (step b).
  • step a step b
  • 8-bromo-l,6-naphthyridine can be formed via cyclization (step a), then bromination with bromine.
  • step a step b
  • step a step b
  • the finally targeted compounds can be obtained by substitution the chlorine of 4- chloro-6-(chloromethyl)pyrimidine with corresponding amines respectively (step a, b).
  • step a step b
  • the finally targeted compounds can be obtained by substitution the chlorine of 4- chloropyrimide core with N-Boc-piperazine (step a) followed de-Boc group treatment with acid (step b), following Michael addition reaction treatment with acrylonitrile (step c).
  • the finally targeted compounds may be formed by reduced animation using NaBH(OAc) 3 or NaBH 3 CN (step a).
  • the finally targeted compounds may be formed by de-Boc group under acid condition (step a) followed reduced amination using NaBH(OAc)3 or NaB]3 ⁇ 4CN (step b).
  • the finally targeted compounds can be obtained by substitution the bromine of 4- (bromomethyl)-6-chloropyrimidine with corresponding amines firstly (step a), then substitution the chlorine of 6-chloropyrimidine with corresponding amines (step b).
  • heteroaromatic derivatives could be synthesized via the reductive amination (step a)followed by substitution with corresponding amine (step b).
  • the (2-methylpyrimidin-5-yl)methanol containing targeted compounds could be synthesized from 2-methylpyrimidine-4,6-diol.
  • the Vilsmeier-Haack reaction with DMF and POCI 3 (step a) followed by reduction aldehyde to alcohol with NaBH 4 (step a); protection of the alcohol group with TBSCI (step b), and then home reaction with trifluoroborate(step c).
  • Oxidation of the double bind to aldehyde with ozone step c
  • the reductive animation step d
  • step e the reductive animation followeded by displacement of the pyrimidine chlorine with corresponding amines
  • the TBS protective group could be removed under the acid condition.
  • methyl ester of quinoline core could be reduced to alcohol by NaBH 4 or LiAlH 4 .
  • step b ⁇ ⁇ step c ⁇
  • the finally targeted compounds can be obtained by substitution the bromine of 5- bromo-2-(bromomethyl)imidazo[l,2- ]pyridine with corresponding amines firstly (step a) followed by substitution the bromine of 5-bromoimidazo[l,2- ]pyridine core with 1- methylpiperazine(step b), following introduction of hydroxymethyl group at 3-position of imidazo[l,2-a]pyridine core under formaldehyde condition (step 3).
  • the finally targeted compound can be synthesized by fluorination of the commercially 6,7-dihydroquinolin-8(5H)-one using selectfluoro (step a), then the reduced amination of ketone with methyl amine (step b), following by alkylation with 4-chloro-6- (chloromethyl)-2-methylpyrimidine (step c), and finally substitution withl- methylpiperazine(step d).
  • the finally targeted compounds may be formed by reduced amination with corresponding aldehydes using NaBH(OAc)3 or NaB]3 ⁇ 4CN (step a).
  • the finally targeted compounds may be formed by substitution with aryl halogen under base, high temperature condition (step a).
  • the finally targeted compounds may be formed by Buchwald coupling reaction with aryl halogen Pd 2 (dba) 3 , BINAP, Cs 2 C0 3 condition (step a).
  • the finally targeted compound may be formed by de-Boc group under the acid condition (step a) followed condensation using HATU (step b).
  • the halogen of quinoline core could be converted to cyano group under the condition of Pd(PPh 3 ) 4 , dppf, and zinc cyanide or Pd 2 (dba) 3 , dppf, and zinc cyanide.
  • the finally targeted compounds could be synthesized from 8-fluoroquinoline.
  • the nitrification with HNO 3 step a) followed by displacement of the aryl fluorine with corresponding amines (step b).
  • the nitro group can be reduced to the amino group with SnCl 2 (step c) and then mesylation with MsCl (step d).
  • Step a 6-(chloromethyl)-2-(methylthio)pyrimidin-4-ol: To a solution of ethyl 4- chloro-3- oxobutanoate (13 g, 79 mmol) and methyl carbamimidothioatesulphate (20 g, 72 mmol) in water (200 mL) was added sodium carbonate (11.5 g, 108 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with 6M HC1 aqueous solution to pH acid and filtered. The filter cake was dried to give the desired product (11.1 g,
  • H NMR 400 MHz, CDC1 3 ) ⁇ 7.23 (s, IH), 4.53 (s, 2H), 2.58 (s, 3H).
  • Step a 6-(chloromethyl)-2-methylpyrimidin-4-ol: To a solution of ethyl 4-chloro- 3- oxobutanoate (16.5 g, 100 mmol) and acetamidine hydrochloride (10 g, 106 mmol) in ethanol (150 mL) was slowly added DBU (30.4 g, 200 mmol) at 4 °C. The reaction was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was dissolved in dichloromethane (120 mL), then washed with brine (30 mL x 3). The organic layer was dried over Na 2 S0 4 and concentrated to give the desired product (7.93 g, 50%) as a yellow oil.
  • H NMR 400 MHz, CDC1 3 ) ⁇ 13.01 (s, 1H), 6.53 (s, 1H), 4.37 (s, 2H), 2.50 (s, 3H).
  • Step b 4-chloro-6-(chloromethyl)-2-methylpyrimidine: The solution of 6- (chloromethyl)-2- methylpyrimidin-4-ol (7.93 g, 50 mmol) in POCI 3 (20 mL) was heated to 110 °C, and stirred for 30 min. Then reaction mixture was concentrated and dissolved in ethyl acetate (20 mL), then added this solution into ice water (100 mL), extracted with ethyl acetate (30 mL x 3). The combined organic layer was dried over Na 2 S0 4 and concentrated.
  • Step c. 2-methyl-6-((methylamino)methyl)pyrimidin-4-ol The solution of 6- (chloromethyl)-2- methylpyrimidin-4-ol (1.7 g, 11 mmol), methylamine solution (30 wt percent in absolute ethanol, 3 g), KI (183 mg, 1.1 mmol) and DIPEA (7.1 g, 55 mmol) in CH 3 CN (50 mL) was added into a sealed tube, and heated to 60 °C. The reaction was stirred at this temperature overnight.
  • Step d N-methyl-l-(2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methanamine: To a solution of 2-methyl-6-((methylamino)methyl)pyrimidin-4-ol (300 mg, 1.96 mmol), TEA (1.9 g, 19.6 mmol) and N-methylpiperazine (980 mg, 9.8 mmol) in CH 3 CN (20 mL) was added PyBOP (1.1 g, 2.15 mmol). The reaction mixture was stirred at reflux overnight.
  • Step b 4-(dimethoxymethyl)-2-methyl-6-(4-methylpiperazin-l-yl)pyrimidine: To a solution of 6-(dimethoxymethyl)-2-methylpyrimidin-4-ol (110 mg, 0.6 mmol), TEA (600 mg, 6 mmol) and N-methylpiperazine (90 mg, 0.9 mmol) in CH 3 CN (10 mL) was added PyBOP (340 mg, 0.7 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH 3 CN, added saturated NaHCC>3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step c. 2-methyl-6-(4-methylpiperazin-l-yl)pyrimidine-4-carbaldehyde The mixture of 4-(dimethoxymethyl)-2-methyl-6-(4-methylpiperazin-l-yl)pyrimidine (140 mg, 0.5 mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the saturated NaHCC>3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the crude desired product (110 mg, 97%) as a yellow oil.
  • Step a 6-(dimethoxymethyl)-2-(methyltliio)pyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy-3-oxobutanoate (3 g, 17 mmol) and methyl carbamimidothioatesulphate (9.5 g, 34 mmol) in water (100 mL) was added K 2 CO 3 (17.6 g, 76.5 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with AcOH to adjust pH to acid and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column
  • Step b 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylthio)pyrimidine: To a solution of 6-(dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol (3.4 g, 16 mmol), TEA (16 g, 160 mmol) and N-methylpiperazine (2.4 g, 40 mmol) in CH 3 CN (100 mL) was added PyBOP (9g, 17.6 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH 3 CN, added saturated NaHCC>3 aqueous solution (200 mL) and extracted with dichloromethane (200 mL).
  • Step c 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylsulfonyl)pyrimidine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)- 2-(methylthio)pyrimidine (2.8 g, 9.4 mmol) in THF (90 mL) and water (4.5 mL) was added Oxone (7 g, 11 mmol). The reaction was stirred at room temperature for 4h. Then the reaction was added saturated NaHCC>3 aqueous solution (200 mL) and extracted with ethyl acetate (200 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the desired product (2.4 g, 78%) as a yellow oil.
  • Step d 4-(dimethoxymethyl)-N,N-dimethyl-6-(4-methylpiperazin-l-yl)pyrimidin- 2-amine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylsulfonyl)pyrimidine (340 mg, 1 mmol) in THF (5 mL) in a sealed tube was added dimethylamine (5 mL). The reaction mixture was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCC>3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step e 2-(dimethylamino)-6-(4-methylpiperazin-l-yl)pyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-N,N-dimethyl-6-(4-methylpiperazin-l-yl)pyrimidin-2- amine (260 mg, 1.3 mmol) and sulfuric acid(20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the saturated NaHCC>3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3).
  • Step f 4-(dimethoxymethyl)-2-ethoxy-6-(4-methylpiperazin-l-yl)pyrimidine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-(methylsulfonyl)pyrimidine (200 mg, 0.61 mmol) in ethanol (5 mL) was added sodium ethanolate (206 mg, 3 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCC>3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step g. 2-ethoxy-6-(4-methylpiperazin-l-yl)pyrimidine-4-carbaldehyde The mixture of 4-(dimethoxymethyl)-2-ethoxy-6-(4-methylpiperazin-l-yl)pyrimidine (160 mg, 0.5 mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, and the saturated NaHCC>3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the crude desired product (100 mg, 80%) as a yellow solid.
  • Step h 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-phenylpyrimidine: The mixture of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-(methylthio)pyrimidine (298 mg, 1 mmol), phenylboronic acid (244 mg, 2 mmol), copper(I) thiophene-2-carboxylate (497 mg, 2.6 mmol) and Pd(PPh 3 ) 4 (115 mg, 0.1 mmol) in THF (20 mL) was stirred at reflux overnight under N 2 atmosphere.
  • Step i 6-(4-methylpiperazin-l-yl)-2-phenylpyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-phenylpyrimidine (240 mg, 0.73 mmol) and sulfuric acid (20 wt percent in water, 10 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, and washed with diethyl ether (10 mL). The water phase was added 6M NaOH aqueous solution to adjust pH to 10 and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step a ethyl 2,4-difluoro-3-oxobutanoate: To a solution of NaH (60 wt percent moistened with oil, 936 mg, 23.4 mmol) in diethyl ether (50 mL) was added dropwise ethyl 2- fluoroacetate (5 g, 47.2 mmol) at room temperature. The reaction was stirred at 40°C for 4h. The reaction mixture was cooled to 0°C and poured into 2M sulfuric acid aqueous solution (15 mL). The mixture was extracted with diethyl ether (50 mL x 3). The combined organic layer was dried over Na2S0 4 , filtered and evaporated. The residue was purified by silica gel column
  • Step b 5-fluoro-6-(fluoromethyl)-2-methylpyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy- 3-oxobutanoate (1.9 g, 11.4 mmol) and acetamidine hydrochloride (2.2 g, 22.8 mmol) in ethanol (40 mL) was added EtONa (2.3 g, 34.2 mmol). The reaction was stirred at reflux overnight. The mixture was cooled to room temperature. 6M HC1 aqueous solution (2 mL) was added and evaporated.
  • Step c. 5-fluoro-4-(fluoromethyl)-2-methyl-6-(4-methylpiperazin-l- yl)pyrimidine To a solution of 5-fluoro-6-(fluoromethyl)-2-methylpyrimidin-4-ol (800 mg, 5 mmol), TEA (1.5 g, 15 mmol) and N-methylpiperazine (750 mg, 7.5 mmol) in C3 ⁇ 4CN (10 mL) was added PyBOP (2.9 g, 5.5 mmol). The reaction mixture was stirred at reflux overnight.
  • Step d l-(5-fluoro-2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4-yl)-N- methylmethanamine: The mixture of 5-fluoro-4-(fluoromethyl)-2-methyl-6-(4-methylpiperazin- l-yl)pyrimidine (1.0 g, 4.1 mmol) and 2M methyl amine (in methanol, 6 mL) in water (15 mL) and i-propanol (15 mL) in a sealed tube was stirred at reflux overnight. The reaction solution was evaporated to remove most of i-propanol, and extracted with dichloromethane (30 mL x 3).
  • Step a (5)-tert-butyl 2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-l-carboxylate: To a mixture of Boc-L-Proline-OH (5 g, 23 mmol), 2,2-dimethyl-l,3-dioxane-4,6-dione (3.4 g, 23 mmol) and DMAP (5.7 g, 46 mmol) in dichloromethane (70 mL) was added DCC (4.8 g, 23 mmol) at 0 °C. The mixture was stirred at room temperature for 48 h before the reaction mixture was filtered.
  • Step b (5)-tert-butyl 2-(6-hydroxy-2-(methylthio)pyrimidin-4-yl)pyrrolidine-l- carboxylate: To a solution of (5)-tert-butyl 2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-l- carboxylate (500 mg, 1.8 mmol) and methyl carbamimidothioatesulphate (1.0 g, 3.6 mmol) in water (25 mL) was added K 2 CO 3 (1.1 g, 8.1 mmol). The reaction was stirred at room
  • Step c. (5)-4-(4-methylpiperazin-l-yl)-2-(methylthio)-6-(pyrrolidin-2- yl)pyrimidine To a solution of (S)-tert-butyl 2-(6-hydroxy-2-(methylthio)pyrimidin-4- yl)pyrrolidine-l-carboxylate (200 mg, 0.64 mmol), TEA (650 mg, 6.4 mmol) and N- methylpiperazine (100 mg, 0.96 mmol) in CH 3 CN (5 mL) was added PyBOP (510 mg, 0.96 mmol). The reaction mixture was stirred at reflux overnight.
  • reaction solution was evaporated to remove most of CH 3 CN, added dichloromethane (100 mL) to dilute, washed with saturated NaHCC>3 aqueous solution (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step a i ⁇ ?ri-butyl 5-oxo-5-(pyridin-2-yl)pentylcarbamate: To a THF solution (30 mL) containing commercially available 2-bromopyridine (1.4 g, 9 mmol) and ⁇ , ⁇ , ⁇ '- ⁇ '- tetramethyl ethylene diamine (960 mg, 6.5 mmol), a hexane solution (3 mL, 7.5 mmol) of 2.5M n-butyl lithium was added dropwise at -78°C, and the resulting solution was stirred at the same temperature for 2h.
  • tert-butyl 2-oxopiperidine-l-carboxylate (1 g, 5 mmol) was added at -78°C, and the resulting solution was stirred at the same temperature for 2h.
  • water (10 mL) was added, and the solution was extracted with ethyl acetate (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated.
  • Step a 2-(bromomethyl)-4-chloropyrimidine: To a solution 4-chloro-2- methylpyrimidine (370 mg, 2.9 mmol), NBS (566 mg, 3.2 mmol) and AIBN (50 mg, 0.3 mmol) in CC1 4 (10 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCC>3 aqueous solution (50 mL) and extracted with
  • Step a 4-hydroxy-2,6-dimethylpyrimidine-5-carbonitrile: To a solution of methyl (Z)-ethyl 2-cyano-3-ethoxybut-2-enoate (5.0 g, 27 mmol) and acetamidine hydrochloride (3.9 g, 41 mmol) in ethanol (80 mL) was added K 2 CO 3 (11.3 g, 82 mmol). The reaction was stirred at room temperature overnight. The mixture was concentrated, added 3M HCl aqueous solution to adjust pH to 5 and extracted with n-butanol (50 mL x 6). The combined organic layer was evaporated to give the desired product (3.5 g, 87%) as a yellow solid. ! H NMR (400 MHz, DMSO-i3 ⁇ 4) ⁇ 13.30 (s, 1H), 2.39 (s, 3H), 2.35 (s, 3H).
  • Step b feri-butyl 4-(5-cyano-2,6-dimethylpyrimidin-4-yl)piperazine-l- carboxylate: To a solution of 4-hydroxy-2,6-dimemylpyrimidine-5-carbonitrile (2.5 g, 16.8 mmol), TEA (5.1 g, 50.4 mmol) and i ⁇ ?ri-butyl piperazine-l-carboxylate (4.7 g, 25.2 mmol) in CH 3 CN (60 mL) was added PyBOP (9.6 g, 18.5 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated.
  • Step c. i ⁇ ?ri-butyl 4-(6-(chloromethyl)-5-cyano-2-methylpyrimidin-4- yl)piperazine-l-carboxylate A mixture of feri-butyl 4-(5-cyano-2,6-dimethylpyrimidin-4- yl)piperazine-l-carboxylate (10 g, 60 4.0 g, 12.6 mmol) in DCM (100 mL) was added TCCA (2.9 g, 12.6 mmol) at 0°C, and the resulting solution was stirred at the same temperature for lh, then stirred at room temperature for 6h.
  • TCCA 2.9 g, 12.6 mmol
  • the reaction was quenched with the saturated Na 2 S 2 0 3 aqueous solution.
  • the reaction mixture was filtered and the filtrate was extracted with dichloromethane (50 mL x 3).
  • the combined organic layer was washed with brine and dried over Na 2 S0 4 , filtered and evaporated.
  • the residue was purified by silica gel column
  • Step d feri-butyl 4-(5-cyano-2-methyl-6-((methyl(l,2,3,4-tetrahydronaphthalen-
  • Step b step c
  • Step a ethyl 5-bromoimidazo[l,2-a]pyridine-2-carboxylate: The solution of methyl 6- bromopyridin-2-amine (1.7 g, 10 mmol) and ethyl 3-bromo-2-oxopropanoate (2.3 g , 12 mmol) in ethanol (80 mL) was stirred at reflux overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was dried by oil pump to give the crude desired product (2.8 g) as a white solid. !
  • Step a N-methyl-l-(3-methylpyridin-2-yl)ethanamine: To a solution of l-(3- methylpyridin-2- yl)ethanone (500 mg, 3.7 mmol) in THF (10 mL) was added methylamine solution (30 wt percent in absolute ethanol, 14.8 mL) and Ti(OEt) 4 (1.7 g, 7.4 mmol). The reaction mixture was stirred for lOmin at room temperature, before NaB3 ⁇ 4 (563 mg, 14.8 mmol) was added, this reaction mixture was stirred for 2h at room temperature.
  • Step b (5)- l-(4-methoxyphenyl)-N-((5)-l-(pyridin-2-yl)ethyl)ethanamine and (5)-l-(4- methoxyphenyl)-N-((R)-l-(pyridin-2-yl)ethyl)ethanamine:
  • the solution of l-(pyridin- 2-yl)ethanone (605 mg, 5 mmol) in dichloromethane (30 mL) was added NaBH(OAc)3 (2.12 mg, 10 mmol) and (S)- l-(4-methoxyphenyl)ethanamine (755 mg, 5 mmol) at 0 °C.
  • Step c. (5)- l-(4-methoxyphenyl)-N-methyl-N-((5)- l-(pyridin-2- yl)ethyl)ethanamine: The solution of (5)- l-(4-methoxyphenyl)-N-((5)- l-(pyridin-2- yl)ethyl)ethanamine (500 mg, 2 mmol) and formaldehyde (37 wt percent in water, 1 mL) in dichloromethane (20 mL) was added NaBH(OAc) 3 (636 mg, 3 mmol). The resulting suspension was stirred at room temperature overnight.
  • Step d. (5)-N-methyl-l-(pyridin-2-yl)ethanamine: To a solution of (5)-l-(4- methoxyphenyl)-N- methyl-N-((5)-l-(pyridin-2-yl)ethyl)ethanamine (400 mg, 1.48 mmol) in dichloromethane (10 mL) was added TFA (5 mL). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated and 1M HCl aqueous (15 mL) was added. The water phase was wash with ethyl acetate (10 mL x 3).
  • Step a 8-chloro-5,6,7,8-tetrahydroquinoline: A mixture of 5,6,7,8- tetrahydroquinoline (10 g, 60 mmol) in DCM (200 mL) was added TCCA (21 g, 90 mmol) and stirred at reflux overnight. The reaction mixture was filtered and the filtrate was solution was added saturated NaHC0 3 aqueous solution (50 mL). The organic layer was dried over Na2S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step b N-ethyl-5,6,7,8-tetrahydroquinolin-8-amine: The solution of 8-chloro- 5,6,7,8- tetrahydroquinoline (500 mg, 3 mmol) in ethylamine/ethanol (10 mL) in a sealed tube was stirred at reflux overnight. Then the reaction solution was concentrated and added saturated NaHC0 3 aqueous solution (5 mL) and extracted with dichloromethane (10 mL x 3).
  • Step a 5'H-spiro[cyclopropane-l,7'-quinolin]-8'(6'H)-one: To a solution of NaH (60 wt percent moistened with oil, 420 mg, 10.5 mmol) in DMF (50 mL) was added dropwise 6,7-dihydroquinolin-8(5H)-one (441 mg, 3.0 mmol) and 1,2-dibromoethane (1.95g, 10.5 mmol) in DMF (5 mL) in sequence at 0°C under N 2 atmosphere. The reaction was stirred at 0°C for lh.
  • Step a.7',8'-dihydro-5'H-spiro[cyclopropane-l,6'-quinoline] To a solution of spiro[2.5]octan-6-one (667 mg, 6 mmol) in ethanol (25 mL) was added prop-2-yn-l-amine (1.3 g, 24 mmol) and NaAuCl 4 (60 mg, 0.15 mmol) in sequence. The reaction was stirred at 85 °C for 1 day. The reaction mixture was concentrated, diluted with ethyl acetate (30 mL) and washed with saturated NaHCC>3 aqueous solution (15 mL) and saturated brine solution (15 mL).
  • Step a 3-(4-methoxybenzylamino)picolinonitrile: The solution of 3- fluoropicolinonitrile (10 g, 82 mmol), (4-methoxyphenyl)methanamine (16.8 g, 123 mmol) and CS2CO 3 (40 g, 123 mmol) in DMF (50 mL) was stirred at 70°C overnight. The reaction mixture was concentrated, diluted with ethyl acetate (50 mL) and washed with saturated brine solution (20 mL x 3). The organic layer was dried over Na 2 S0 4 , filtered and evaporated.
  • Step b l-(3-(4-methoxybenzylamino)pyridin-2-yl)ethanone: To a solution of 3-
  • Step c. N-(2-acetylpyridin-3-yl)acetamide The solution of l-(3-(4- methoxybenzylamino)pyridin- 2-yl)ethanone (1.5 g, 5.8 mmol) in TFA (5 mL) was stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCC> 3 aqueous solution to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was dissolved in acetate acid (10 mL), and added AC 2 O (20 mL), stirred at room temperature overnight.
  • Step d N-(2-acetylpyridin-3-yl)methanesulfonamide: The solution of l-(3-(4- methoxybenzylamino)pyridin-2-yl)ethanone (1.3 g, 5.1 mmol) in TFA (7 mL) was stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCC>3 to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated.
  • Step a 4-oxo-4-(pyridin-2-yl)butanal: To a solution of Mg powder (1.06 g, 44 mmol) and I2 (20 mg, 0.08 mmol) in THF (15 mL) was added drop wise the solution of 2-(2- bromoethyl)-l,3-dioxolane (7.16 g, 40 mmol) in THF (15 mL). The reaction mixture was stirred at room temperature for 1.5h. Then this mixture was cooled to 0°C and added drop wise to a THF (10 mL) containing picolinonitrile (2.08 g, 20 mmol) at 0°C. The reaction mixture was stirred at this temperature for 1.5h.
  • Step b 2-((5)-l-((R)-l-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine: The solution of 4-oxo-4-(pyridin-2-yl)butanal (490 mg, 3 mmol) in dichloromethane (20 mL) was added NaBH(OAc) 3 (1.9 g, 9 mmol) and AcOH (20 mg, 0.33 mmol) at -70°C. The resulting suspension was stirred at the same temperature for 30 min. The reaction was warmed to 0°C and added (R)- l-(4- methoxyphenyl)ethanamine (500 mg, 3.3 mmol).
  • Step c. (5)-2-(pyrrolidin-2-yl)pyridine The solution of 2-((5)- l-((R)-l-(4- methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine (400 mg, 1.48 mmol) in TFA (5 mL) was stirred at 50°C for 12h. The reaction mixture was concentrated and 1M HC1 aqueous (15 mL) was added. This solution was wash with dichloromethane (5 mL x 3). Then saturated NaHC0 3 solution was added to adjust pH to 9, and extracted with dichloromethane (10 mL x 5). The combined organic layer was dried over Na2S0 4 , filtered and evaporated to give the desired product (110 mg, 50%) as a colorless oil.
  • Step d 2-((R)-l-((5)-l-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine: The solution of 4-oxo-4-(pyridin-2-yl)butanal (326 mg, 2 mmol) in dichloromethane (15 mL) was added NaBH(OAc) 3 (1.27 g, 6 mmol) and HOAc (20 mg, 0.33 mmol) at -70°C. The resulting suspension was stirred at the same temperature for 30 min. The reaction was warmed to 0°C and added (5)-l-(4- methoxyphenyl)ethanamine (332 mg, 2.2 mmol).
  • Step e. (R)-2-(pyrrolidin-2-yl)pyridine The solution of 2-((R)-l-((5)-l-(4- methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine (400 mg, 1.48 mmol) in TFA (5 mL) was stirred at 50°C for 12h. The reaction mixture was concentrated and 1M HC1 aqueous (15 mL) was added. This solution was wash with dichloromethane (5 mL x 3). Then saturated NaHCC>3 solution was added to adjust pH to 9, and extracted with dichloromethane (10 mL x 5). The combined organic layer was dried over Na2S0 4 , filtered and evaporated to give the desired product (100 mg, 45%) as a colorless oil.
  • Step a N-(diphenylmethylene)-l-(pyridin-2-yl)methanamine: To the solution of pyridin-2- ylmethanamine (3.97g, 37 mmol) and benzophenone (6.69 g, 37 mmol) in toluene (50 mL) was added p-TsOH (10 mg, 0.058 mmol). The mixture was stirred at reflux overnight. The reaction solution was cooled to room temperature and washed with saturated NaHCC>3 solution (30 mL x 2). The organic layer was dried over Na2S0 4 , filtered and evaporated to give the crude desired product (10 g) as a yellow oil.
  • Step b ethyl 4-(diphenylmethyleneamino)-3-methyl-4-(pyridin-2-yl)butanoate:
  • the solution of crude N-(diphenylmethylene)-l-(pyridin-2-yl)methanamine (1.5 g), NaOH solution (50 wt percent in water, 110 mg, 2.75 mmol) and BnEtsNCl (60 mg, 0.3 mmol) in acetonitrile (50 mL) was stirred at room temperature for 30 min. Then (£ " )-ethyl but-2-enoate (630 mg, 5.5 mmol) was added. The mixture was stirred at room temperature overnight.
  • Step c. 4-methyl-5-(pyridin-2-yl)pyrrolidin-2-one The solution of crude ethyl 4- (diphenylmethyleneamino)-3-methyl-4-(pyridin-2-yl)butanoate (1.3 g) in acetonitrile (15 mL) was added drop wise concentrated HC1 aqueous (3 mL). The mixture was stirred at room temperature for 2h. The reaction solution was washed with dichloromethane (10 mL x 2). The water phase was diluted with acetonitrile (15 mL) and added dropwise ammonia water (5 mL). The mixture was stirred at room temperature for 5h. Then the reaction solution was extracted with dichloromethane (10 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Step d. 2-(3-methylpyrrolidin-2-yl)pyridine The solution of 4-methyl-5-(pyridin- 2-yl)pyrrolidin- 2-one (200 mg, 1.1 mmol) in THF (5 mL) was added LiAlH 4 (174 mg, 4.5 mmol) in portions. The mixture was stirred at reflux overnight. Water (1 mL), NaOH solution (10 wt percent in water, 1 mL) and Water (1 mL) were added in sequence. The mixture was filtered and the filtrate was evaporated to give the desired product (89 mg, 50%) as a yellow oil.
  • Step a (£ ' )-2-(pyridin-2-ylmethyleneamino)acetonitrile: The solution of 2- aminoacetonitrile hydrochloride (5.09 g, 55 mmol) and TEA (9.09 g, 90 mmol) in ethanol (250 mL) was added stirred at room temperature for 30 min. Then picolinaldehyde (5.36 g, 50 mmol) was added. The mixture was stirred at room temperature overnight. The reaction solution was concentrated and dissolved in Et20 (200 mL). The mixture was filtered and the filtrate was evaporated to give the crude desired product (4.8 g) as a yellow oil.
  • Step c. ds-ethyl 2-(pyridin-2-yl)pyrrolidine-3-carboxylate: To the solution of crude ds-ethyl 5-cyano-2-(pyridin-2-yl)pyrrolidine-3-carboxylate (245 mg, 1 mmol) in THF (5 mL) was added 1M BH 3 /THF solution (2 mL, 2 mmol), and stirred for 20 min. Then cooled to 0°C, NaBH 4 (76 mg, 2 mmol) was added. The mixture was stirred at the same temperature for 3h before room temperature overnight.
  • Step a 6-methyl-8-nitroquinoline:
  • the pure glycerol (5.0 g, 54 mmol) was heated to 150°C for 30 min. Then it was cooled to 110°C, and added 4-methyl-2-nitroaniline (3.0 g, 20 mmol) and Nal (60 mg, 0.40 mmol). The mixture was heated to 150°C again, and added concentrated sulfuric acid (4.51 g, 46 mmol). The resulting suspension was stirred at this temperature for lh. The reaction mixture was cooled to room temperature and added water (20 mL). This water phase was extracted with dichlorome thane (20 mL x 4). The combined organic layer was evaporated.
  • Step b 6-methylquinolin-8-amine: To the solution of 6-methyl-8-nitroquinoline (350 mg, 1.86 mmol) in methanol (30 mL) was added Pd/C (10 wt percent, 0.2 g), and stirred at room temperature under N2 atmosphere overnight. The mixture was filtered and the filtrate was evaporated to give the crude desired product (250 mg, 85%) as a yellow oil.
  • H NMR 400 MHz, CDCI 3 ) ⁇ 8.69 (s, IH), 7.98 (s, IH), 7.33 (s, IH), 6.94 (s, IH), 6.79 (s, IH), 4.90 (s, 2H), 2.43 (s, 3H).
  • Step a N,6-dimethylquinolin-8-amine hydroiodide: To the solution of 6- methylquinolin-8-amine (250 mg, 1.58 mmol) in ethanol (10 mL) in a sealed tube was added CH 3 I (337 mg, 2.37 mmol), and stirred at reflux overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with diethyl ether (10 mL) and the filer cake obtained was dried by oil pump to give the crude desired product hydroiodide (200 mg, 42%) as a red solid.
  • Step a 5,6,8-trifluoroquinoline: To the solution of concentrated sulfuric acid (18 mL) diluted with water (6 mL), was added 2,4,5-trifluoroaniline (3.68 g, 25 mmol), glycerol (4.60 g, 50 mmol) and sodium 3-nitrobenzenesulfonate (6.75 g, 30 mmol) in sequence. The resulting suspension was stirred at 140°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCC>3 aqueous solution to adjust pH to 7, extracted with dichloromethane (200 mL x 2). The combined organic layer was evaporated.
  • step b 5,6-difluoro-N-methylquinolin-8-amine: To the solution of 5,6,8- trifluoroquinoline (436 mg, 2.38 mmol) and K 2 CO 3 (657 mg, 4.76 mmol) in DMSO (3 mL) in a sealed tube, was added MeN3 ⁇ 4 solution (30 wt percent in ethanol, 3 mL). The resulting suspension was stirred at 120°C for 2 days. The reaction mixture was cooled to room
  • Step a l,7-naphthyridin-8-amine: To the solution of concentrated sulfuric acid (15 mL) diluted with water (15 mL), was added pyridine-2, 3 -diamine (1.09 g, 10 mmol), glycerol (4.1g, 33.6 mmol) and sodium 3-nitrobenzenesulfonate (4.5 g, 20.1 mmol) in sequence. The resulting suspension was stirred at 125°C overnight. The reaction mixture was cooled to room temperature and added saturated NaOH aqueous solution to adjust pH to 8, extracted with dichloromethane (100 mL x 2). The combined organic layer was evaporated.
  • step b 8-chloro-l,7-naphthyridine: To the solution of l,7-naphthyridin-8-amine (290 mg, 2.0 mmol) in concentrated HCl aqueous solution (5 mL), was added NaN0 2 (1.38 g, 20 mmol) and CuCl (238 mg, 33.6mmol) in sequence. The resulting suspension was stirred at room temperature for 3h. The reaction mixture was added saturated NaHC0 3 aqueous solution to adjust pH to 8, extracted with ethyl acetate (100 mL x 3). The combined organic layer was evaporated.
  • Step a 1,6-naphthyridine: To the solution of concentrated sulfuric acid (30 mL) diluted with water (20 mL), was added pyridin-4-amine (3.76 g, 40.0 mmol), glycerol (12.52 g, 136 mmol) and sodium 3-nitrobenzenesulfonate (19.8 g, 88.0 mmol) in sequence. The resulting suspension was stirred at 130°C overnight. The reaction mixture was cooled to room
  • step b 8-bromo-l,6-naphthyridine: To the solution of 1,6-naphthyridine (830 mg, 6.38 mmol) in HOAc (5 mL), was added dropwise dibromine (612 mg, 3.83 mmol). The resulting suspension was stirred at 80°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCC>3 aqueous solution to adjust pH to 8, extracted with dichloromethane (100 mL x 3). The combined organic layer was evaporated.
  • step b 4-chloro-l,5-naphthyridine: The solution of 1,5-naphthyridine 1-oxide (3.0 g, 20.5 mmol) in POCI 3 (30 mL), was stirred at 100°C for 6h. The reaction mixture was concentrated and diluted with dichloromethane (100 mL). This solution was added saturated NaHCC>3 aqueous solution to adjust pH to 8. Filtered and the filtrate was partitioned. The water phase was extracted with ethyl acetate (100 mL). The combined organic layer was evaporated.
  • Step a N-(2-(pyridin-2-yl)propan-2-yl)formamide: To the solution of 2-(pyridin- 2-yl)propan-2-amine (350 mg, 2.6 mmol) in toluene(10 mL), was added formic acid (237 mg, 5.2 mmol). The resulting suspension was stirred at reflux for 6h. The reaction mixture was cooled to room temperature and added saturated NaHCC>3 aqueous solution (50 mL), the water phase was extracted with dichloromethane (50 mL). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography
  • Step b N-methyl-2-(pyridin-2-yl)propan-2-amine: To the solution of N-(2- (pyridin-2-yl)propan-2-yl)formamide (300 mg, 1.8 mmol) in THF (10 mL), was added NaH (60 wt percent moistened with oil, 222 mg, 5.4 mmol). The resulting suspension was stirred at room temperature for 15 min. Then CH 3 I (390 mg, 2.7 mmol) was added, the reaction mixture was stirred at reflux for 2h. The reaction mixture was cooled to room temperature and added the solution of NaOH (252 mg, 6.12 mmol) in methanol (5 mL) and water (1 mL). The reaction mixture was stirred at reflux overnight. The reaction mixture was cooled to room temperature and extracted with dichloromethane (100 mL x 3). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography
  • step a step b
  • Method AA-Step a N-((6-chloropyrimidin-4-yl)methyl)-N-methyl-5, 6,7,8- tetrahydroquinolin-8- amine: A mixture of N-methyl-5,6,7,8-tetrahydroquinolin-8-amine (160 mg, 1 mmol, see reference WO2006026703), 4-chloro-6-(chloromethyl)pyrimidine (170 mg, 1.05 mmol), KI (16 mg, 0.1 mmol) and DIPEA (320 mg, 2.5 mmol) in CH 3 CN (10 mL) was stirred at room temperature overnight.
  • Method AA-Step b N-methyl-N-((6-(4-methylpiperazin- l-yl)pyrimidin-4- yl)methyl)-5,6,7,8- tetrahydroquinolin-8-amine: A mixture of N-((6-chloropyrimidin-4- yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8-amine (100 mg, 0.35 mmol), TEA (350 mg, 3.5 mmol) and N-methylpiperazine (40 mg, 0.38 mmol) in ethanol (4 mL) was stirred at reflux overnight.
  • Method AB-Step a tert-butyl-4-(6-((methyl(5,6,7,8-tetrahydroquinolin-8- yl)amino)methyl)pyrimidin-4-yl)piperazine-l-carboxylate: A mixture of N-((6-chloropyrimidin- 4- yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine (200 mg, 0.7 mmol), TEA (700 mg, 7 mmol) and tert-butyl piperazine-l-carboxylate (140 mg, 0.77 mmol) in ethanol (10 mL) was stirred at reflux overnight.
  • reaction mixture was added saturated NaHCC>3 aqueous solution (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Method AB-Step b N-methyl-N-((6-(piperazin- l-yl)pyrimidin-4-yl)methyl)- 5,6,7,8- tetrahydroquinolin-8-amine: To a solution of tert-butyl-4-(6-((methyl(5,6,7,8- tetrahydroquinolin-8- yl)amino)methyl)pyrimidin-4-yl)piperazine-l-carboxylate (270 mg, 0.6 mmol) in dichloromethane (5 mL) was added dropwise 3M HC1/ ethyl acetate (5 mL). The mixture was stirred at room temperature for 12 h.
  • Method AC-Step a N-methyl-N-((2-methyl-6-(4-methylpiperazin- 1 -yl)pyrimidin- 4-yl)methyl)- 5,6,7,8-tetrahydroquinolin-8-amine: A mixture of N-methyl-5, 6,7,8- tetrahydroquinolin-8-amine (37 mg, 0.23 mmol, see reference WO2006026703), 2-methyl-6-(4- methylpiperazin-l-yl)pyrimidine-4- carbaldehyde (46 mg, 0.21 mmol) and AcOH (13 mg, 0.21 mmol) in 1,2-dichloroethane (5 mL) was stirred for 10 min. NaBH(OAc)3 (66 mg, 0.3 mmol) was then added to the reaction solution. The resulting suspension was stirred at room
  • Method AD-Step a (5)-N-methyl-N-((2-methyl-6-((R)-2-methylpiperazin- l- yl)pyrimidin-4- yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: To a solution of (R)-tert-butyl 3- methyl-4-(2-methyl-6- ((methyl((5)-5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4- yl)piperazine-l-carboxylate (50 mg, 0.11 mmol) in ethyl acetate (2 mL) was added 3M HQ/ ethyl acetate (3 mL) and stirred at room temperature overnight.
  • reaction mixture was added saturated NaHCC>3 aqueous solution (50 mL) and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na2S0 4 , filtered and evaporated to give the desired product (26 mg, 65%) as a colorless oil.
  • Method AD-Step b (5)-N-((6-((R)-2,4-dimethylpiperazin-l-yl)-2- methylpyrimidin-4-yl)methyl)- N-methyl-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of (5)- N-methyl-N-((2-methyl-6-((R)-2- methylpiperazin-l-yl)pyrimidin-4-yl)methyl)-5, 6,7,8- tetrahydroquinolin-8-amine (26 mg, 0.07 mmol) and formaldehyde (37 wt percent in water, 30 mg, 0.36 mmol) in 1,2-dichloroethane (4 mL) was added NaBH(OAc)3 (30 mg, 0.14 mmol).
  • Method AE-Step a N-((4-chloropyrimidin-2-yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8- amine: The mixture of 2-(bromomethyl)-4-chloropyrimidine(94 mg, 0.58 mmol), N-methyl-5,6,7,8- tetrahydroquinolin-8-amine (130 mg, 0.6 mmol, see reference WO2006026703), KI (10 mg, 0.06 mmol) and DIPEA (740 mg, 5.8 mmol) in MeCN (10 mL) was stirred at room temperature for 4h.
  • Method AE-Step b N-methyl-N-((4-(4-methylpiperazin- l-yl)pyrimidin-2- yl)methyl)-5,6,7,8- tetrahydroquinolin-8-amine: The mixture of N-((4-chloropyrimidin-2- yl)methyl)-N-methyl-5, 6,7,8- tetrahydroquinolin-8-amine (50 mg, 0.17 mmol), DIPEA (244 mg, 1.7 mmol) and 1-methylpiperazine (87 mg, 0.85 mmol) in NMP (2 mL) was stirred at 200 °C under microwave for 2 h.
  • Method AF-Step a N-((6-bromopyridin-2-yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8- amine: The mixture of 6-bromopicolinaldehyde (162 mg, 0.68 mmol), N- methyl-5,6,7,8- tetrahydroquinolin-8-amine (100 mg, 0.62 mmol, see reference
  • Method AF-Step b N-methyl-N-((6-(4-methylpiperazin- l-yl)pyridin-2- yl)methyl)-5,6,7,8- tetrahydroquinolin-8-amine: The mixture of N-((6-bromopyridin-2- yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8-amine (50 mg, 0.15 mmol), DIPEA (193 mg, 1.5 mmol) and 1-methylpiperazine (73 mg, 0.75 mmol) in NMP (2 mL) was stirred at 120 °C overnight.
  • Method AG-Step a N-methyl-N-(pyrimidin-4-ylmethyl)-5,6,7,8- tetrahydroquinolin-8-amine: A mixture of N-((6-chloropyrimidin-4-yl)methyl)-N-methyl- 5,6,7,8-tetrahydroquinolin-8-amine (70 mg, 0.24 mmol) and Pd/C (5 %, 15 mg) in 5 mL of methanol was stirred at 50 °C under 3 ⁇ 4 (1 atm) overnight. The reaction solution was filtered and the filtrate was evaporated.
  • Method AH-Step a (4,6-dichloro-2-methylpyrimidin-5-yl)methanol: To POCl 3 (60.6 g, 396.5 mmol) was added dropwise DMF (9.8 g, 134.8 mmol) at 0°C. The resulting suspension was stirred at the same temperature for lh. Then 2-methylpyrimidine-4,6-diol (10 g, 79.3 mmol) was added in portions and stirred at room temperature for lh, after that, stirred at 105 °C overnight. The reaction solution was concentrated and diluted with cold ethyl acetate (lOOmL).
  • Method AH-Step b 5-((feri-butyldimethylsilyloxy)methyl)-4,6-dichloro-2- methylpyrimidine: To the solution of (4,6-dichloro-2-methylpyrimidin-5-yl)methanol (2 g, 10.3 mmol) and imidazole (770 mg, 11.3 mmol) in dichloromethane (20mL) was added TBSC1 (1.7 g, 11.3 mmol) in portions. The resulting suspension was stirred at room temperature overnight. Water (20 mL) was added, and extracted with dichloromethane (20 mL). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated.
  • Method AH-Step e (5)-(2-methyl-4-((methyl(l-(pyridin-2- yl)ethyl)amino)methyl)-6-(4- methylpiperazin-l-yl)pyrimidin-5-yl)methanol: The mixture of (5)-(4-chloro-2-methyl-6-((methyl(l- (pyridin-2-yl)ethyl)amino)methyl)pyrimidin-5- yl)methanol (50 mg, 0.16 mmol), TEA (80 mg, 0.8 mmol) and l-methylpiperazine (48 mg, 0.48 mmol) in ethanol (5 niL) was stirred at reflux overnight. The reaction solution was evaporated. The residue was purified by silica gel column chromatography
  • reaction mixture was added saturated NaHC0 3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the desired product (35 mg, 86%) as a white solid.
  • Method AJ-Step a (8-(methyl((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methyl)amino)quinolin-6-yl)methanol: The solution of methyl 8-(methyl((2-methyl-6-(4- methylpiperazin- 1 -yl)pyrimidin-4-yl)methyl)amino)quinoline-6-carboxylate( 105 mg, 0.25 mmol) in THF (3 mL) was added L1AIH 4 (19 mg, 0.5 mmol) at 0°C, and stirred at room temperature for 20 min. Water and NaOH aqueous solution (15wt percent in water) was added to quench the reaction.
  • Method AK-Step a (5)-5-bromo-2-((2-(3-methylpyridin-2-yl)pyrrolidin-l- yl)methyl)imidazo[l,2- jpyridine: The mixture of 5-bromo-2-(bromomethyl)imidazo[l,2- ]pyridine(48 mg, 0.17mmol), (5)-3-methyl-2-(pyrrolidin-2-yl)pyridine (30 mg, 0.12 mmol), KI (3 mg, 0.017 mmol) and K 2 C0 3 (46 mg, 0.34 mmol) in MeCN (15 mL) was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated.
  • Method AL-Step a 7,7-difluoro-6,7-dihydroquinolin-8(5H)-one: To a solution of NaH (60 wt percent moistened with oil, 511 mg, 12.8 mmol) in THF (20 mL) was added dropwise the THF solution (5 mL) containing 6,7-dihydroquinolin-8(5H)-one (588 mg, 4 mmol) at 0°C. The reaction was stirred at 0°C for 10 min followed by adding selectfluro (3.0 g, 8.4 mmol) in portions. The reaction mixture was stirred at room temperature for lh. Water (20 mL) was added to quench the reaction.
  • Method AL-Step b.7,7-difluoro-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine The solution of 7,7-difluoro-6,7-dihydroquinolin-8(5H)-one (18.3 mg, 0.1 mmol), MeNH 2 solution (30 wt percent in ethanol, 1 mL) and HO Ac (5 mg, 0.083 mmol) in 1,2-dichloroethane (2 mL) was added NaBHsCN (13 mg, 0.2 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated.
  • Method AM-Step a N-methyl-N-((2-methyl-6-(4-methylpiperazin- 1 - yl)pyrimidin-4- yl)methyl)quinolin-8-amine: A mixture of N-((2-methyl-6-(4-methylpiperazin-l- yl)pyrimidin-4- yl)methyl)quinolin-8-amine (75 mg, 0.26 mmol) and formaldehyde (37 wt percent in water, 42 mg, 0.52 mmol) in methanol (3 mL) was added NaB3 ⁇ 4CN (25 mg, 0.4 mmol). The resulting suspension was stirred at room temperature overnight. Water (10 mL) was added to quench the reaction.
  • Method AN-step a N-methyl-N-((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin- 4-yl)methyl)- l,7-naphthyridin-8-amine: To the solution of 8-chloro-l,7-naphthyridine (56 mg, 0.34 mmol) and N- methyl- l-(2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4-yl)methanamine (80 mg, 0.34 mmol) in DMSO (3 mL), was added K 2 C0 3 (140 mg, 1.02 mmol). The resulting suspension was stirred at 110°C overnight. The reaction mixture was concentrated.
  • Method AO-step a N-methyl-N-((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-
  • Method AP-Step a 4-(((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methyl)(quinolin-8- yl)amino)butanoic acid: The solution of feri-butyl 4-(((2-methyl-6-(4- methylpiperazin-l-yl)pyrimidin- 4-yl)methyl)(quinolin-8-yl)amino)butanoate (55 mg, 0.112 mmol) in concentrated HCl aqueous solution (6 mL) was stirred at 50°C overnight. The reaction mixture was evaporated to give the desired product hydrochloride (535 mg, 96%) as a yellow oil.
  • Method AP-Step b 4-(((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methyl)(quinolin-8- yl)amino)butanamide: The mixture of 4-(((2-methyl-6-(4- methylpiperazin-l-yl)pyrimidin-4- yl)methyl)(quinolin-8-yl)amino)butanoic acid (50 mg, 0.098 mmol), NH 4 C1 (27 mg, 0.51 mmol), HATU (47 mg, 0.122 mmol) and DIPEA (131 mg, 1.02 mmol) in DMF (3 mL) was stirred at 50°C overnight. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography
  • the reaction mixture was stirred at room temperature for lh.
  • the 2M NaOH aqueous solution was added to adjust pH to 11 and stirred for lh.
  • the mixture was partitioned and the water phase was added 6MHC1 aqueous solution to adjust pH to 5.
  • the saturated NaHCC>3 aqueous solution was added to adjust pH to 8 and extracted with ethyl acetate (30 mL x 3).
  • the combined organic layer was evaporated.
  • Method AA-Step b (5)-N-methyl-N-((2-methyl-6-(4-methylpiperazin- 1 - yl)pyrimidin-4-yl)methyl)- l-(pyridin-2-yl)ethan-l-amine: A mixture of (5)-N-((6-chloro-2- methylpyrimidin-4-yl)methyl)-N-methyl-l-(pyridin-2-yl)ethan-l -amine (90 mg, 0.33 mmol), TEA (333 mg, 3.3mmol) and N-methylpiperazine (163 mg, 1.6 mmol) in ethanol (10 mL) was stirred at reflux overnight. The reaction mixture was concentrated.
  • Method AK-Step a (5)-N-((5-bromoimidazo[l,2- ]pyridin-2-yl)methyl)-N- methyl- l-(pyridin-2-yl)ethan- l-amine: The mixture of 5-bromo-2-(bromomethyl)imidazo[l,2- jpyridine (127 mg, 0.4 mmol), (5)-N-methyl-l-(pyridin-2-yl)ethanamine (55 mg , 0.4 mmol), KI (7 mg, 0.04 mmol) and DIPEA (130 mg, 1 mmol) in MeCN (10 mL) was stirred at room temperature overnight. The reaction mixture was evaporated.
  • Method AK-Step b (5)-N-methyl-N-((5 -(4-methylpiperazin- l-yl)imidazo[l, 2- ]pyridin-2-yl)methyl)- l-(pyridin-2-yl)ethan-l -amine: The mixture of (5)-N-((5- bromoimidazo[ 1 ,2- ]pyridin-2-yl)methyl)-N- methyl- 1 -(pyridin-2-yl)ethan- 1-amine (100 mg , 0.29 mmol) in N-methylpiperazine (3 mL) was stirred at 190°C under microwave for 2 h. The reaction mixture was concentrated. The residue was purified by silica gel column
  • reaction mixture was added saturated NaHCC>3 aqueous solution (10 mL) and extracted with dichloromethane (20 mL). The organic layer was dried over Na2S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
  • Table 1 shows a selection of the compounds prepared according to the methods discussed above in details and indicated in the third column of the table.
  • A5 A AA 2.57 (s, 6H), 2.39 (s, 3H), 2.11 (s, IH), 2.00 (s, IH),
  • HPB-ALL cells were maintained in RPMI-1640 (Gibico) supplemented with 10% FBS (Hyclone).
  • APC-conjugated anti-human CXCR4 was from Surgie. ECso was first determined for 12G5 binding to CXCR4. Then the compounds for testing were added into 96- well plates serially diluted at a ratio of 1:3. Cells were washed once with ice-cold assay buffer (DPBS+2% HI-FBS) and then re-suspended in the same buffer at a final concentration of 1 x 10 6 /mL.
  • DPBS+2% HI-FBS ice-cold assay buffer
  • Tables 2 summarize results of the CXCR4 competitive binding assay for selected compounds disclosed in the present disclosure.
  • Table 3 summarizes results of the CXCR4 competitive binding assay for control compounds.
  • FIGs. 1-2 depict the IC 50 curves of compounds A42 and A43. [00408] Table 2. Results of selected compounds of the present invention tested by thel2G5 binding assay
  • the FLIPR Tetra calcium mobilization assay was performed by HD Bioscience. Briefly, The Molecular Devices, Fluorescent Imaging Plate Reader (FLIPR) Tetra was used in this assay. Excitation was achieved through unique placement of LED' s within the instrument and emission captured by a CCD camera (EMCCD camera for FI and ICCD camera for luminescence). The homogeneous FLIPR Calcium 4 assay kit from Molecular Devices was used as the fluorescence reagent. Compounds were solubilized in 100% dimethyl sulfoxide (DMSO) to a concentration of 30 mM.
  • DMSO dimethyl sulfoxide
  • a 10-point, 4-fold, intermediate dilution series was created in 100% DMSO with a top concentration of 4 mM and a bottom concentration of 0.01 ⁇ .
  • a near assay ready, direct dilution plate (ddNARP) was prepared from this compound dilution plate by transferring 1 ⁇ ⁇ of each dilution of compound in 100% DMSO to a Greiner#781201 plate.
  • each ddNARP plate also contained positive and negative control wells to define the upper and lower limits for the assay signal.
  • the final assay concentration range of compound was 10 ⁇ to 0.035 nM in 0.5% DMSO.
  • Human CD 4+ T-Cells were isolated from human whole blood and subsequently activated and expanded using a CD3/CD28 expansion kit (Life Technologies). The cells were frozen in ThermoFisher-formulated Recovery Cell Culture Freezing Medium containing 10% Dimethyl sulfoxide (DMSO) and 10% Fetal Bovine Serum (FBS) (ThermoFisher Catalog No. 10100147). When used, cells were resuspended using room temperature IX HBSS/20mM HEPES/0.005% P-104 assay buffer, adjusted the volume of the suspension to achieve a cell concentration of 2.5 x 10 6 cells/mL.2X Calcium 4 dye (20 ⁇ ⁇ ) were added and the mixture were centrifuged briefly ( ⁇ 10s) and stopped when it reached 1000 rpm.
  • DMSO Dimethyl sulfoxide
  • FBS Fetal Bovine Serum
  • the plates were allowed to equilibrate before compounds and CXCL12 were added to the plates.
  • the raw data were analyzed using Abase.
  • the percent (%) effect at each concentration of compound was calculated by Abase and was based on and relative to the amount of calcium produced in the positive and negative control wells contained within each assay plate.
  • the concentrations and % effect values for tested compounds were plotted by Abase and the concentration of compound required for 50% effect (IC 50 ) was determined with a four-parameter logistic dose response equation.
  • Table 4 summarizes the results of selected compounds in the calcium mobilization assay.
  • FIGs. 3 and 4 summarize the results of Compounds A78 and A83 in the calcium mobilization assay.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18859565.6A 2017-09-25 2018-09-24 Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon Pending EP3687540A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710875041 2017-09-25
CN201810265417.9A CN110317191B (zh) 2018-03-28 2018-03-28 一种吡啶杂环化合物及其作为cxcr4抑制剂的应用
CN201810710340.1A CN110669036B (zh) 2018-07-02 2018-07-02 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用
CN201811034891.7A CN109553604B (zh) 2017-09-25 2018-09-05 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
PCT/US2018/052503 WO2019060860A1 (en) 2017-09-25 2018-09-24 HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF

Publications (2)

Publication Number Publication Date
EP3687540A1 true EP3687540A1 (de) 2020-08-05
EP3687540A4 EP3687540A4 (de) 2021-04-21

Family

ID=65809950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859565.6A Pending EP3687540A4 (de) 2017-09-25 2018-09-24 Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon

Country Status (3)

Country Link
EP (1) EP3687540A4 (de)
KR (1) KR102678977B1 (de)
WO (1) WO2019060860A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156595A1 (en) 2017-02-21 2018-08-30 Emory University Chemokine cxcr4 receptor modulators and uses related thereto
WO2019183133A1 (en) 2018-03-19 2019-09-26 Emory University Pan-Tropic Entry Inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789045A2 (de) * 2004-08-16 2007-05-30 Smithkline Beecham Corporation Chemische verbindungen
JP2008511669A (ja) * 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
US20080207634A1 (en) * 2004-12-17 2008-08-28 Kristjan Gudmundsson Chemical Compounds
US20080234318A1 (en) * 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
DK2262808T3 (da) * 2008-03-28 2013-11-04 Altiris Therapeutics Chemokinreceptormodulatorer
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
US10709697B2 (en) * 2015-07-16 2020-07-14 Emory University Bis-amines, compositions, and uses related to CXCR4 inhibition
US11332470B2 (en) * 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2019060860A1 (en) 2019-03-28
KR102678977B1 (ko) 2024-06-28
EP3687540A4 (de) 2021-04-21
KR20200058443A (ko) 2020-05-27

Similar Documents

Publication Publication Date Title
EP3687540A1 (de) Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon
AU2016225896C1 (en) Heterocyclic compounds useful as PDK1 inhibitors
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
JP2022518860A (ja) 免疫調節剤、組成物およびその使用方法
EP4304720A1 (de) Mta-kooperative prmt5-hemmer
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
WO2005066171A1 (en) Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2006118598A1 (en) Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JP6782766B2 (ja) ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−ベンジルテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
KR20170075756A (ko) 카르바졸 유도체
CN112110938B (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
EP3860998B1 (de) Verbindungen und zusammensetzungen zur behandlung von erkrankungen in zusammenhang mit der apj-rezeptoraktivität
CN117242056A (zh) 用作sting激动剂的新型化合物及其用途
CN112823159B (zh) 一类具有激酶抑制活性的芳香杂环类化合物
CN111875583B (zh) 三氮唑衍生物及其制备方法和用途
US11964987B2 (en) Isoidide derivatives and methods of making and using same
JP7282786B2 (ja) Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
CN110669036B (zh) 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用
CN109553604B (zh) 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CA3179671A1 (en) Kinase inhibitors and uses thereof
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN109956929B (zh) 杂环衍生物、其制备方法、药物组合物及应用
WO2019196918A1 (zh) 五元杂环并嘧啶类化合物、药物组合物及用途
KR102655210B1 (ko) 아데노신 a2a 수용체 길항제 및 이의 용도
CN112409332B (zh) 三氮唑衍生物及其在药物中的应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210208BHEP

Ipc: A61P 11/00 20060101ALI20210208BHEP

Ipc: A61P 35/00 20060101ALI20210208BHEP

Ipc: C07D 401/14 20060101ALI20210208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210324

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210318BHEP

Ipc: C07D 401/14 20060101ALI20210318BHEP

Ipc: A61P 11/00 20060101ALI20210318BHEP

Ipc: A61P 35/00 20060101ALI20210318BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220802